UroGen Pharma (URGN) Share-based Compensation Growth (5y) (2022 - 2026)

UroGen Pharma (URGN) Share-based Compensation Growth (5y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 UroGen Pharma 2.05 Bn 1.91 Bn 46.82 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -5.67%
Dec 31, 2025 -13.67%
Sep 30, 2025 21.08%
Jun 30, 2025 20.78%
Mar 31, 2025 -16.62%
Dec 31, 2024 29.70%
Sep 30, 2024 -13.59%
Jun 30, 2024 -13.17%
Mar 31, 2024 -18.03%
Dec 31, 2023 -21.71%
Sep 30, 2023 -25.23%
Jun 30, 2023 -22.03%
Mar 31, 2023 -12.83%
Dec 31, 2022 -30.04%